GENNIEFY
Market News
Latest financial news and analysis from global markets
XAU/USD
Gold Rises as Iranian Proposal Raises Hopes for US-Tehran Deal
(Bloomberg) -- Gold rose amid hopes for a deal to end the standoff between the US and Iran that’s dashed expectations for rate cuts from central banks across the world.Most Read from BloombergUS Seeks to Deploy Hypersonic Missile for the First Time Against IranTwo NJ Malls Separated by Just Four Miles — and Very Different FatesTrump Family-Backed Drone Firm Signs Weapons Deal With USTrump Says Iran Blockade ‘Incredible’ as Pump Prices Keep RisingNorth Korea Confirms Suicide Rule for Soldiers Ukr
USD/JPY
What are the chances of a second round of government intervention?
Investing.com -- Japan’s recent currency intervention to support the yen may be followed by another round of action as early as the coming days, according to a report by Bank of America, which highlights recurring patterns in past interventions.
NKE
Nike’s Bottom May Have to Wait for a Dow Exit. What the Charts Say.
Year to date, the group has lagged the consumer discretionary sector, outperforming little beyond the struggling gaming cohort. There are pockets of resilience, with Crocs and On Holding AG attempting comebacks, but former category leader Nike has clearly lost its footing. Nike still trades nearly 50% below its 52-week high from last summer.
MS
Sustained China Export Demand Bolsters Mobileye’s (MBLY) 2026 Outlook According to Morgan Stanley
With a street-high upside potential of 192.5%, Mobileye Global Inc. (NASDAQ:MBLY) ranks among the 10 best robotics stocks to buy under $30. Mobileye Global Inc. (NASDAQ:MBLY) delivered a strong first quarter, and on April 27, 2026, Morgan Stanley updated its view on the stock, reducing its price target to $10 from $12 while maintaining its […]
MRNA
Moderna’s Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway.
Moderna defied expectations of a Covid-revenue slowdown on Friday as a surge in international vaccine sales underpinned its first-quarter results. Revenue more than tripled in Moderna’s latest quarter to $389 million from $108 million last year, handily beating analysts’ calls for $236.4 million. Moderna logged a $1.34 billion net loss, or $3.40 a share.
MRK
Moderna’s Covid Vaccine Is Driving Growth Again. The Stock Is Down Anyway.
Moderna defied expectations of a Covid-revenue slowdown on Friday as a surge in international vaccine sales underpinned its first-quarter results. Revenue more than tripled in Moderna’s latest quarter to $389 million from $108 million last year, handily beating analysts’ calls for $236.4 million. Moderna logged a $1.34 billion net loss, or $3.40 a share.
TSLA
Tesla stock higher for week as Semi starts production, company nets $573M in sales from SpaceX, xAI last year
Tesla stock is poised to finish the day and week higher, following last week's drop in the wake of earnings.
PFE
Eli Lilly Stock’s Path To 30% Upside
Beneath Eli Lilly's (LLY) headline numbers lies a structural business model shift that the broader market seems to currently undervalue, driven in part by a recent valuation penalty following Novo Nordisk's faster initial prescription ramp for its oral therapy. While early volume data favors the competitor’s established brand capture, the central equity debate remains focused on the friction between high demand and pricing pressure from pharmacy benefit managers. Critics highlight dropping reali
MRK
Eli Lilly Stock’s Path To 30% Upside
Beneath Eli Lilly's (LLY) headline numbers lies a structural business model shift that the broader market seems to currently undervalue, driven in part by a recent valuation penalty following Novo Nordisk's faster initial prescription ramp for its oral therapy. While early volume data favors the competitor’s established brand capture, the central equity debate remains focused on the friction between high demand and pricing pressure from pharmacy benefit managers. Critics highlight dropping reali
JNJ
Eli Lilly Stock’s Path To 30% Upside
Beneath Eli Lilly's (LLY) headline numbers lies a structural business model shift that the broader market seems to currently undervalue, driven in part by a recent valuation penalty following Novo Nordisk's faster initial prescription ramp for its oral therapy. While early volume data favors the competitor’s established brand capture, the central equity debate remains focused on the friction between high demand and pricing pressure from pharmacy benefit managers. Critics highlight dropping reali
BTCUSDT
Crypto Youtubers Predict Bitcoin Bottom and Bear Market Cycle
Two YouTubers - Carl Runefelt and David Wulschner - say Bitcoin bottomed at $60K, citing missing euphoria and steady institutional demand.
TSLA
Tesla Sold SpaceX $143 Million Worth Of Cars: SEC Filing
An updated SEC filing disclosed Tesla's sale of electric vehicles to CEO Elon Musk's other company SpaceX. Tesla stock is up about 1%.